ABBV—I don’t think it’s company-specific. Big Pharma have had a bit of a run-up lately, possibly a result of the FTC’s being rebuffed in its attempts to block mergers.
The Abbott breakup has been very good for both companies with Abbvie actually doing better. The sleeper that I have always had a high opinion of is Lilly and they have doubled the outstanding results of Abbvie or Abbott.
Sadly I had a large position that I whittled down in the early 2006-8 era.
News 
Market Data 
Discover 
AI
